Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC
Medical Oncology, 07/16/2012
Zupa A et al. – The identification and the biological and clinical characterization of novel EGFR mutations represent a prerequisite for their wide use as predictive biomarkers for personalized therapy in Non–small–cell lung cancer (NSCLC).



